Palatin Technologies, Inc. (PTN)
$8.19-4.21%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $15M
- Beta
- -0.07
- P/E (TTM)
- -1.56
- Short % float
- 26.38%
- Days to cover
- 8.0
- SI change
- +1.0%
- 1W
- -12.96%
- 1M
- -38.70%
- vs SPY 1W
- -12.83%
- vs SPY 1M
- -41.20%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 0
- GROWTH
- 58
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-69.0%
REV YoY-
ROE-65.2%
EPS YoY-
ROA-98.3%
GROSS100
OP-66
NET-64
[VALUATION]
P/E TTM-1.56
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B4.80
P/FCF-
EV/EBITDA-0.87
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.35
ALTMAN Z-
CURR RATIO4.61
ND/EBITDA-
BETA-0.07
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on PTN?
- LOPJLB’s latest quantitative signal on Palatin Technologies, Inc. (PTN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PTN in?
- Palatin Technologies, Inc. (PTN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Palatin Technologies, Inc. (PTN) do?
- Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial…